Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study

Frontiers in Medicine

Medicine

Ya-Ting Zhang¹  Dun-Hua Zhou²  Ke Huang²  Jian-Pei Fang²  Lu-Hong Xu²  Xin-Yu Li²  Xia-Wei Han²  Hong-Gui Xu³ 

[1] Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;

关键词: Chidamide;    T-cell acute lymphoblastic leukemia;    children;    chemotherapy;    hematopoietic stem cell transplantation;   

DOI  :  10.3389/fmed.2023.1096529

 received in 2022-11-12, accepted in 2023-01-16,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundThe long-term overall survival of children with T-cell acute lymphoblastic leukemia (T-ALL) is limited to approximately 80–85% because of a high incidence of relapse after achieving remission with intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Novel treatment strategies inducing long-term remission are needed to improve the outcome. Histone deacetylase inhibitors (HDACis) have been reported to be effective in a series of T-ALL cases. Preclinical studies suggested that T-ALL cells are sensitive to Chidamide, which is a selective HDACi.MethodsThis preliminary clinical study evaluated the efficacy and safety of Chidamide in combination with chemotherapy or post-HSCT for children with T-ALL at a dose of 0.5 mg/kg weight of patient twice per week for at least 6 months.ResultsIn total, 27 children with a mean age of 7.88 years were included. The high-risk proportion was 66.7%. After a median follow-up period of 37.8 months (9.5–67.9 months), the overall survival and event-free survival in the patients treated with Chidamide were 94.1 and 95.2%, respectively. All patients except two maintained persistent remission with <0.01% blast cells in minimal residual disease.ConclusionThe combination therapy with Chidamide in a case series of T-ALL shows the promising clinical efficacy and good safety in children.Clinical trial registrationhttps://www.chictr.org.cn/, identifier ChiCTR2000030357.

【 授权许可】

Unknown   
Copyright © 2023 Li, Han, Huang, Zhang, Xu, Zhou, Xu and Fang.